Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website.

Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.
Pre-admission glucagon-like peptide-1 receptor agonist (GLP-1RA) and mortality from coronavirus disease 2019 (Covid-19): A systematic review, meta-analysis, and meta-regression

Timotius Ivan Hariyanto a, Denny Intana a, Joshua Edward Hananto a, Cynthia Putri a, Andree Kurniawan b,*

a Faculty of Medicine, Pelita Harapan University, Karawaci, Tangerang 15811, Indonesia
b Department of Internal Medicine, Faculty of Medicine, Pelita Harapan University, Karawaci, Tangerang 15811, Indonesia

ARTICLE INFO

Article history:
Received 25 July 2021
Received in revised form 20 August 2021
Accepted 26 August 2021
Available online 28 August 2021

Keywords:
Coronavirus disease 2019
Covid-19
Diabetes
GLP-1RA
Anti-diabetic

ABSTRACT

Aims: GLP-1RA has many beneficial properties, including anti-inflammatory, anti-obesogenic, pulmonary protective effects as well as beneficial impact on gut microbiome. However, the evidence regarding the benefit of GLP-1RA in Covid-19 patients with diabetes is still unclear. This study sought to analyze the benefit of pre-admission use of GLP-1RA in altering the mortality outcomes of coronavirus disease 2019 (Covid-19) patients with diabetes mellitus.

Methods: Using specific keywords, we comprehensively searched the potential articles on PubMed, Europe PMC, and medRxiv database until June 12th, 2021. All published studies on Covid-19 and GLP-1RA were retrieved. Statistical analysis was conducted using Review Manager 5.4 and Comprehensive Meta-Analysis version 3 software.

Results: A total of 9 studies with 19,660 diabetes mellitus patients who were infected by SARS-CoV-2 were included in the meta-analysis. Our data suggested that pre-admission use of GLP-1RA was associated with reduction in mortality rate from Covid-19 in patients with diabetes mellitus (OR 0.53; 95% CI: 0.43–0.66, \( p < 0.00001 \), \( I^2 = 0\%\), random-effect modelling). Further analysis showed that the associations were not influenced by age (\( p = 0.213 \)), gender (\( p = 0.421 \)), hypertension (\( p = 0.131 \)), cardiovascular disease (\( p = 0.293 \)), nor the use of metformin (\( p = 0.189 \)) and insulin (\( p = 0.117 \)).

Conclusions: Our study suggests that pre-admission use of GLP-1RA may offer beneficial effects on Covid-19 mortality in patients with diabetes mellitus. However, more randomized clinical trials are required to confirm this conclusion.

© 2021 Elsevier B.V. All rights reserved.

1. Introduction

The emergence of Covid-19 disease since the first case on December 2019 had caused up to 177,108,695 confirmed cases, including 3,840,223 deaths per June 2021 according to WHO.[1] Cases’ severity varied among all age populations depending on their comorbidities. Diabetes mellitus and obesity were found to be two of important risk factors which may...
contribute to the development of severe form of Covid-19, causing further inflammation and immune dysfunction that leads to the formation of cytokines storm which is life threatening.[2-7] Several therapies had been proposed to control this storm and manage these conditions.[8-14] Recently the use of GLP1-RA, as one alternative to treat DM patients, had shown promising effect to reduce excessive inflammation-induced acute lung injury and improving Covid-19 outcome.[15] In addition to stimulating postprandial insulin secretion, GLP1-RA also seems to have beneficial properties such anti-inflammatory, anti-obesogenic, pulmonary protective effects and gut microbiome modulating effects.[16] Furthermore, an experimental study on rats showed that the use of GLP1-RA (liraglutide) was capable to stimulate pulmonary ACE2 expression, an enzyme that has been demonstrated to oppose the pathway that is responsible for the progression of acute respiratory distress syndrome (ARDS), including the one caused by SARS-CoV-2 infection.[17,18] However, the evidences regarding benefit of GLP1-RA in Covid-19 patients are still unclear. Therefore, the objective of this study is to evaluate and analyze the association between GLP1-RA and Covid-19 mortality.

2. Materials and methods

2.1. Eligibility criteria

The protocol of this study was registered in PROSPERO (CRD42021260638). The articles analyzed in this study has qualified the following entry criteria: fulfill the PICO framework (P: patients with diabetes mellitus who were infected with SARS-CoV-2; I: pre-admission use of GLP1-RA; C: the use of any other anti-diabetic drugs besides GLP1-RA prior to admission into the hospital; O: mortality from Covid-19), cohort, case-control, cross-sectional, and randomized or non-randomized clinical trial studies were included. All studies aside from original research articles (review articles, letter to editor or correspondence), case-series or case report studies, studies presented in any other language besides English, articles focusing on people below 18 years of age and pregnant women were excluded.

2.2. Search strategy and study selection

The articles from three databases (PubMed, Europe PMC, and medRxiv) were searched systematically. Search terms used include “GLP-1” OR “GLP-1RA” OR “glucagon-like peptide-1” OR “dulaglutide” OR “semaglutide” OR “exenatide” OR “liraglutide” AND “diabetes” OR “diabetes mellitus” AND “SARS-CoV-2”, OR “coronavirus disease 2019” OR “Covid-19” in a time range from 2019 until June 12, 2021 with English-language restriction. Our searching strategy details are listed in Table 1. Initial screening of titles and abstracts was conducted to identify eligible articles. Searches of potential articles were also done by analyzing the list of references of eligible studies. The strategy for searching the article was presented in the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) diagram.

2.3. Data extraction and quality assessment

Two researchers (TIH, DI) performed the data extraction. Every essential information about the study, including the characteristic of the population (age, gender, hypertension, cardiovascular disease, metformin and insulin usage/consumption), the number of patients who use GLP-1RA, as well as the mortality in Covid-19 patients were listed and arranged in one form.

| Database   | Keyword                                                                 | Result |
|------------|-------------------------------------------------------------------------|--------|
| PubMed     | (“glucagon-like peptide 1”[MeSH Terms] OR “glucagon-like peptide 1”[All Fields] OR “glp 1”[All Fields]) OR GLP-1RA[All Fields] OR (“dulaglutide”[Supplementary Concept] OR “dulaglutide”[All Fields]) OR (“semaglutide”[Supplementary Concept] OR “semaglutide”[All Fields]) OR (“exenatide”[MeSH Terms] OR “exenatide”[All Fields]) OR (“liraglutide”[MeSH Terms] OR “liraglutide”[All Fields]) AND (“diabetes mellitus”[MeSH Terms] OR (“diabetes”[All Fields] AND “mellitus”[All Fields]) OR “diabetes mellitus”[All Fields] OR “diabetes insipidus”[MeSH Terms] OR (“diabetes”[All Fields] AND “insipidus”[All Fields]) OR “diabetes insipidus”[All Fields]) AND (“COVID-19”[All Fields] OR “COVID-19”[MeSH Terms] OR “COVID-19 Vaccines”[All Fields] OR “COVID-19 Vaccines”[MeSH Terms] OR “COVID-19 serotherapy”[All Fields] OR “COVID-19 Nucleic Acid Testing”[All Fields] OR “covid-19 nucleic acid testing”[MeSH Terms] OR “COVID-19 Serological Testing”[All Fields] OR “covid-19 serological testing”[MeSH Terms] OR “COVID-19 Testing”[All Fields] OR “covid-19 testing”[MeSH Terms] OR “SARS-CoV-2”[All Fields] OR “sars-cov-2”[MeSH Terms] OR “Severe Acute Respiratory Syndrome Coronavirus 2”[All Fields] OR “NCOV”[All Fields] OR “2019 NCOV”[All Fields] OR (“coronavirus”[MeSH Terms] OR “coronavirus”[All Fields] OR “COV”[All Fields]) AND 2019/11/01[DateRange]: 3000/12/31[DateRange]) | 25     |
| Europe PMC | “GLP-1” OR “GLP-1RA” OR “glucagon-like peptide-1” OR “dulaglutide” OR “semaglutide” OR “exenatide” OR “liraglutide” AND “diabetes” AND “diabetes mellitus” AND “SARS-CoV-2”, OR “coronavirus disease 2019” OR “COVID-19” | 156    |
| medRxiv    | “GLP-1” OR “GLP-1RA” OR “glucagon-like peptide-1” OR “dulaglutide” OR “semaglutide” OR “exenatide” OR “liraglutide” AND “diabetes” AND “diabetes mellitus” AND “SARS-CoV-2”, OR “coronavirus disease 2019” OR “COVID-19” | 19     |

Table 1 – Literature search strategy.
Mortality from COVID-19, defined by the total number of patients who died during the follow-up period with positive Covid-19 status, will be the outcome of interest.

Two researchers (JEH, CP) assessed the quality of each study included in this study independently. The case-control and cohort studies’ quality were evaluated by using Newcastle–Ottawa Scale (NOS). The assessment reviews the selection, comparability, and outcome of each study, then each study was assigned a total score from zero to nine. A score of ≥7 is considered a good quality study.[19]

2.4. Statistical analysis

Review Manager 5.4 (Cochrane Collaboration) software and Comprehensive Meta-Analysis version 3 were used to perform the meta-analysis and meta-regression. Generic-Inverse Variance formula was utilized to calculate the odds ratio (OR) and its 95% confidence interval (95 %CI) for the mortality outcome. The heterogeneity was assessed by using the I² statistic with a value of <25%, 26–50%, and >50% were considered as low, moderate, and high degrees of heterogeneity, respectively. Meta-regression with random-effects model was performed using a restricted-maximum likelihood for pre-specified variables including age, gender, hypertension, cardiovascular disease, and the use of metformin. Funnel plot analysis was used to evaluate the qualitative risk of publication bias, while the quantitative risk was assessed by using the Egger’s regression method.[20]

Fig. 1 – PRISMA diagram of the detailed process of selection of studies for inclusion in the systematic review and meta-analysis.
| Study                  | Sample size | Design                  | Country    | Overall age mean ± SD | Male n (%) | Hypertension n (%) | Cardiovascular disease n (%) | Metformin use n (%) | Insulin use n (%) | GLP-1RA use n (%) | Death | Alive |
|-----------------------|-------------|-------------------------|------------|-----------------------|------------|-------------------|-----------------------------|-------------------|------------------|--------------------|-------|-------|
| Cariou B et al. [21]  | 1317        | Retrospective cohort    | France     | 69.8 ± 13             | 855 (64.9%)| 1003 (77.2%)      | 621 (47.1%)                 | 746 (56.6%)       | 504 (38.3%)      | 9 (6.4%)           |       |       |
| Israelsen SB et al. [22] | 996         | Retrospective cohort    | Denmark    | 60 ± 14               | 521 (52.3%)| N/A               | N/A                         | 645 (64.7%)       | 224 (24.8%)      | 14 (26.4%)         |       |       |
| Izzi-Engbeaya C et al. [23] | 337         | Retrospective cohort    | England    | 65.8 ± 17.5           | 202 (60%)  | 238 (70.6%)       | 91 (27%)                    | 169 (50.1%)       | 108 (31%)        | No data on death/alive Total = 5 (1.4%) |       |       |
| Nyland JE et al. [24]  | 12,954      | Retrospective cohort    | USA        | 62.2 ± 15.2           | 6244 (48.2%)| 5881 (45.4%)      | 3420 (26.4%)                | 6192 (47.8%)      | 7435 (57.4%)     | 32 (2.9%)          |       |       |
| Orioli L et al. [25]   | 73          | Retrospective cohort    | Belgium    | 69 ± 14               | 35 (48%)   | 59 (80.8%)        | 32 (43.8%)                  | 45 (61.6%)        | 31 (45.6%)       | 0 (0%)             |       | 5 (8.8%)|
| Ramos-Rincon JM et al. [26] | 790         | Retrospective cohort    | Spain      | 85.8 ± 4.5            | 418 (52.9%)| 666 (84.3%)       | 625 (79.1%)                | 420 (53.1%)       | 211 (26.7%)      | 11 (2.9%)          |       | 13 (3.3%)|
| Silverii GA et al. [27] | 159         | Retrospective cohort    | Italy      | 73.3 ± 12.6           | 86 (54.1%) | N/A               | N/A                         | 76 (47.8%)        | 43 (27%)         | 1 (1.7%)           |       | 6 (6%) |
| Sourij H et al. [28]   | 238         | Retrospective cohort    | Austria    | 71.1 ± 12.9           | 152 (63.9%)| 169 (71%)         | 160 (67.2%)                 | 77 (32.3%)        | 52 (21.9%)       | 0 (0%)             |       | 3 (1.7%)|
| Wargny M et al. [29]   | 2796        | Retrospective cohort    | France     | 69.7 ± 13.2           | 1782 (63.7%)| 2126 (76.8%)      | 302 (11.4%)                 | 1553 (55.6%)      | 1039 (37.2%)     | 33 (5.7%)          |       | 221 (10%)|
3. Results

3.1. Study selection and characteristics

The searches on the databases yielded 195 studies. Through eliminating duplicates articles, a total of 163 records remained to be further assessed. Another 147 studies were removed after screening through the titles and abstracts while matching the inclusion and exclusion criteria. Further evaluation for its eligibility on the remaining 16 full-text articles was completed. A total of 7 articles were excluded in which four articles had no data regarding the mortality in GLP-1RA user compared with non GLP-1RA user, another two have another outcome of interest besides mortality (risk of Covid-19 and hospitalization), and lastly one article also include non-Covid-19 diabetes patients. The details regarding excluded articles can be seen in Appendix A. As a result, 9 studies were included in this meta-analysis[21-29] with an overall of 19,660 Covid-19 patients with diabetes mellitus (Fig. 1). All 9 studies were retrospective cohort studies, and the characteristics of each studies were shown in Table 2.

3.2. Quality of study assessment

Quality assessment of cohort and case-control studies using NOS scale indicated all included studies had a good quality (Table 3). Altogether, all studies were acceptable to be further analyzed using meta-analysis.

3.3. GLP-1RA and mortality outcome

Our pooled analysis showed that pre-admission use of GLP-1RA in diabetes mellitus patients was associated with reduction of mortality rate from Covid-19, with no relevant heterogeneity (OR 0.53; 95 %CI: 0.43-0.66, p < 0.00001, I² = 0%, random-effect modelling) (Fig. 2).

3.4. Meta regression

Our meta-regression suggested the association between pre-admission use of GLP-1RA and mortality from Covid-19 was not affected by age (p = 0.213) (Fig. 3A), gender (p = 0.421) (Fig. 3B), hypertension (p = 0.131) (Fig. 3C), cardiovascular disease (p = 0.293) (Fig. 3D), nor the use of metformin (p = 0.189) (Fig. 3E) and the use of insulin (p = 0.117) (Fig. 3F).

3.5. Publication bias

Funnel plot analysis showed a relatively symmetrical inverted-plot (Fig. 4), while Egger's regression method also showed non-significant result (p = 0.737) for the association between pre-admission GLP-1RA use and mortality outcome, showing no indication of publication bias.

4. Discussion

Our analysis shows that pre-admission use of GLP-1RA is associated with reduced mortality in COVID-19 patients with diabetes research and clinical practice 179 (2021) 109031
diabetes mellitus. This association was not affected by age, gender, hypertension, cardiovascular disease, nor the use of metformin and insulin.

There are some explanations how GLP-1RA could affect the prognosis of Covid-19 patients. Glucagon-like peptide-1 (GLP-1), an incretin hormone, is responsible for facilitating postprandial insulin secretion. GLP-1-based drugs work on GLP-1 receptors (GLP-1R) that are primarily located on epithelial of the lung and immune cells. In COVID-19 patients, with or without DM, GLP-1RA have been considered to have several
mechanisms that may improve the outcome of the disease. Besides their glucose-lowering effects, they serve multiple benefits on controlling lung injury caused by inflammation through pulmonary protective effects, anti-obesogenic properties, and modulation of gut microbiota.[30]

Frequent fluctuations of uncontrolled blood glucose level may build up oxidative stress, causing further production of inflammatory cytokines and dysregulation of the innate and adaptive immunity.[31] Furthermore, there has been a speculation that SARS-CoV-2 viral replication will be promoted in the state of elevated glucose levels.[32,33] Therefore, controlling blood glucose level is important as part of treatment strategy in COVID-19 patients. GLP1-RA is an excellent agent for non-severe COVID-19 (Insulin is still the treatment of choice for severe COVID-19 with type 2 Diabetes) because it has high efficacy in controlling blood glucose level with low risk of hypoglycemia[30] and there is no considerable disadvantage of GLP-1RA that may interfere metabolism in COVID-19 patients with diabetes.[34]

Minor concern regarding GLP-1RA effects on promoting the expression of angiotensin converting enzyme-2 (ACE-2) has also been proposed. To enter pulmonary epithelial cells, SARS-CoV2 attaches to ACE-2 receptors, hence any drug that upregulates the receptor may worsen the outcome of the infection. GLP-1RA may stimulate ACE2 expression, although it still remains unknown whether the drugs increase ACE2 expression in human population.[35,36]

In addition to pancreas, GLP-1-based drugs show anti-inflammatory and immunoregulatory effect in multiple organs. GLP-1R is abundantly expressed in multiple organs including brain, pancreas, kidney, stomach, heart, and predominantly in lung epithelia and immune cells.[37] GLP-1RA mainly express its anti-inflammatory properties through the suppression of cytokine and chemokine production, stimulation of eNOS/sGC/PKG signaling pathway, inactivation of the NF-B signaling, as well as attenuation of thio redoxin-interacting protein levels.[35] Animal studies in mice with experimental lung injury also showed that GLP-1RA reduce mucus secretion, and preserve lung function.[38-42] In addition, Rogliani et al.[43] reported that GLP-1RAs improves forced expiratory volume in 1 s - FEV1, forced vital capacity - FVC, and maximal expiratory flow at 75% and 50% - MEF75 and MEF50 in diabetes mellitus patients, regardless on their blood glucose levels.

GLP-1R expressed copiously in lungs. In an animal study conducted at rats, GLP-1 improved pulmonary physiology and surfactant production.[18] GLP-1 owns anti-inflammatory and anti-atherogenic properties. Several inflammatory markers and cardiovascular markers (e.g. C-reactive protein) are reduced in Type 2 diabetes patients treated with GLP-1RA.[44] GLP-1 inhibited IL-1β production, cytokine secretion, interfere nuclear factor-kB pathway, and promoted survival after lipopolysaccharide induced systemic inflammation in rats. The fact that GLP-1 displays anti-inflammatory effects and GLP-1R presence in the lung further support that GLP-1RA might attenuate acute lung disease.[37,38,45,46]

GLP-1RA also seem to affect the activity of neural pathways involved in food intake, reward, and energy expenditure and thus have the ability to decrease body weight.[47] Long-acting GLP-1RA usage consistently results in significant weight loss.[48-50] Furthermore, liraglutide is also used for treating obesity/overweight patients with hypertension, diabetes, and dyslipidemia as a supporting drug to diet and exercise due to clinically significant weight loss, reduction in blood glucose level variability and multiple cardiometabolic risk factors. Weight reduction properties of GLP-1RA is favorable in overweight/obese COVID-19 patients because high BMI
is associated with multiple drawbacks that increase susceptibility to COVID-19 such as chronic inflammation, high ACE-2 expression, and decreased vitamin D level, thus, decreasing fat mass opposes those risk factors. [48-50]

In an animal study GLP1-RA seems to be capable of reversing gut microbiota dysbiosis (Low Bacteroidetes/Firmicutes ratio) caused by type 2 diabetes mellitus/obesity. It is proposed that GLP-1 modulates gut microbiota by delaying gastric emptying time and gut transit time (thus affecting intraluminal environment), binding to neurons within hypothalamus (interfering gut-brain axis), and modulating appetite, weight loss, and glucose homeostasis. [51] Since dysbiosis causes increased intestinal permeability, endotoxemia, and activation of NF-B and other inflammatory pathways, any infectious diseases including COVID-19 might progress into a more severe form. Hence, the use of GLP-1RA might prevent Covid-19 progression by controlling gut microbiota dysbiosis which was precipitated by diabetes mellitus and/or obesity. [51,52]

We are aware of some limitations in our study. First, our study is only based from observational studies which are not free from the potential influence of confounding factors. Second, most of the included studies do not include information regarding the dosage and the duration of GLP-1RA use, therefore we are unable to analyze and provide drug dose and duration recommendation. Finally, the result from our analysis was dominantly affected by 2 studies which have large weight during the meta-analysis calculation, probably because of large sample sizes, therefore the results from our study should be interpreted with caution.

5. Conclusion

Our meta-analysis indicates that pre-admission use of GLP-1RA have an association with favorable mortality outcomes of Covid-19 in patients with diabetes mellitus. This study suggests that GLP-1RA have the potency to be the drug of choice for the management of type 2 diabetes mellitus patients during COVID-19 pandemic to improve patients’ outcome, especially those who have cardiovascular risk factors. Importantly, we believe further randomized clinical trial studies are worthwhile to confirm our study. Finally, GLP-1RA should be put into consideration as an important agent in COVID-19 treatment plan.

Declaration of Competing Interest

The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.

Acknowledgements

None.

Funding

This research did not receive any specific grant from funding agencies in the public, commercial, or not-for-profit sectors.

Data availability

Data analyzed in this study were a re-analysis of existing data, which are openly available at locations cited in the reference section.

REFERENCES

[1] World Health Organization. Coronavirus disease (COVID-19): situation report. Accessed June 18, 2021. https://www.who.int/publications/m/itemweekly-epidemiological-update-on-covid-19—15-june-2021

[2] Wu ZH, Tang Y, Cheng Q. Diabetes increases the mortality of patients with COVID-19: a meta-analysis. Acta Diabetol 2021 Feb;58(2):139-44. https://doi.org/10.1007/s00592-020-01546-0.

[3] Huang Y, Lu Y, Huang YM, Wang M, Ling W, Sui Y, et al. Obesity in patients with COVID-19: a systematic review and meta-analysis. Metabolism 2020 Dec;113. https://doi.org/10.1016/j.metabol.2020.154378.

[4] Hariyanto TI, Kurniawan A. Dyslipidemia is associated with severe coronavirus disease 2019 (COVID-19) infection. Diabetes Metab Syndr 2020;14(5):1463-5. https://doi.org/10.1016/j.dxsdx.2020.07.054.

[5] Hariyanto TI, Kurniawan A. Obstructive sleep apnea (OSA) and outcomes from coronavirus disease 2019 (COVID-19) pneumonia: a systematic review and meta-analysis. Sleep Med 2021 Jun;82:47-53. https://doi.org/10.1016/j.sleep.2021.03.029.

[6] Putri C, Hariyanto TI, Hananto JE, Christian K, Situmeang RFV, Kurniawan A. Parkinson’s disease may worsen outcomes from coronavirus disease 2019 (COVID-19) pneumonia in hospitalized patients: A systematic review, meta-analysis, and meta-regression S1353-8020(21)00152-8. Parkinsonism Relat Disord 2021. https://doi.org/10.1016/j.parkreldis.2021.04.019.

[7] Hariyanto TI, Rosalind J, Christian K, Kurniawan A. Human immunodeficiency virus and mortality from coronavirus disease 2019: A systematic review and meta-analysis. South Afr J HIV Med 2021 Apr 15;22(1):1220. https://doi.org/10.4102/sajhivmed.v22i1.1220.

[8] Hariyanto TI, Kurniawan A. Metformin use is associated with reduced mortality rate from coronavirus disease 2019 (COVID-19) infection. Obes Med 2020 Sep;19. https://doi.org/10.1016/j.obmed.2020.100290.100290.

[9] Hariyanto TI, Kurniawan A. Dipeptidyl peptidase 4 (DPP4) inhibitor and outcome from coronavirus disease 2019 (COVID-19) in diabetic patients: a systematic review, meta-analysis, and meta-regression. J Diabetes Metab Disord 2021 Mar;27:1-8. https://doi.org/10.1007/s40200-021-00777-4.

[10] Hariyanto TI, Kurniawan A. Statin and outcomes of coronavirus disease 2019 (COVID-19): A systematic review, meta-analysis, and meta-regression. Nutr Metab Cardiovasc Dis 2021 Jun 7;31(6):1662-70. https://doi.org/10.1016/j.numecd.2021.02.020.

[11] Ivan Hariyanto T, Kurniawan A. Tocilizumab administration is associated with the reduction in biomarkers of coronavirus disease 2019 infection. J Med Virol 2021 Mar;93(3):1832-6. https://doi.org/10.1002/jmv.26638.

[12] Hariyanto TI, Hardyson W, Kurniawan A. Efficacy and Safety of Tocilizumab for Coronavirus Disease 2019 (COVID-19) Patients: A Systematic Review and Meta-analysis. Drug Res (Stuttg) 2021 May;71(5):265-73. https://doi.org/10.1055/a-1336-2371.

[13] Hariyanto TI, Halim DA, Jodhinata C, Yanto TA, Kurniawan A. Colchicine treatment can improve outcomes of coronavirus
disease 2019 (COVID-19): A systematic review and meta-analysis. Clin Exp Pharmacol Physiol 2021 Jun;48(6):823–30. https://doi.org/10.1111/1440-1681.13488.

[14] Hariyanto TI, Halim DA, Rosalind J, Gunawan C, Kurniawan A. Ivermectin and outcomes from Covid-19 pneumonia: A systematic review and meta-analysis of randomized clinical trial studies. Rev Med Virol 2021 Mar 22. https://doi.org/10.1002/rmv.2265 e2265.

[15] Pang J, Liu M, Ling W, Jin T. Friend or foe? ACE2 inhibitors and GLP-1R agonists in COVID-19 treatment. Obes Med 2021 https://doi.org/10.1007/s00125-020-05180-x e2265.

[16] Belaı̈ncı̈ć A, Kresoı̈vı̈c A, Troskot DM. Glucagon-like peptide-1 receptor agonists in the era of COVID-19: Friend or foe? Clin Obes 2021 Apr;11(2). https://doi.org/10.1111/cob.12439 e12439.

[17] Kuba K, Imai Y, Rao S, Jiang C, Penninger JM. Lessons from SARS: control of acute lung failure by the SARS receptor ACE2. J Mol Med (Berl) 2006 Oct;84(10):814–20. https://doi.org/10.1007/s00125-006-0094-9 e12439.

[18] Romanı´-Perez M, Outeirıñho-Iglesias V, Moya CM, Santisteban P, González-Matias LC, Vigo E, et al. Activation of the GLP-1 Receptor by Liraglutide Increases ACE2 Expression, Reversing Right Ventricular Hypertrophy, and Improving the Production of SP-A and SP-B in the Lungs of Type 1 Diabetes Rats. Endocrinology 2015 Oct;156(10):5559–69. https://doi.org/10.1210/en.2014-1685.

[19] Margulis AV, Pladevall M, Riera-Guardia N, Santisteban C, Hazell L, Berkman ND, et al. Quality assessment of observational studies in a drug-safety systematic review, comparison of two tools: the Newcastle-Ottawa Scale and the RTI item bank. Clin Epidemiol 2014 Oct;6(10):539–68. https://doi.org/10.2147/CLEP.S66677.

[20] Egger M, Davey Smith G, Schneider M, Minder C. Bias in retrospective study from an academic center in Belgium. Prognosis of in-patients with diabetes and COVID-19: A systematic review and meta-analysis. Clin Exp Pharmacol Physiol 2021 Jun;48(6):823–30. doi.org/10.1111/1440-1681.13488.

[21] Orioli L, Servais T, Belkhir I, Laterre PF, Thissen JP, Vandeleene B, et al. Clinical characteristics and short-term prognosis of in-patients with diabetes and COVID-19: A retrospective study from an academic center in Belgium. Diabetes Metab Syndr 2021;15(1):149–57. https://doi.org/10.1016/j.dsx.2020.12.020.

[22] Ramos-Rincón JM, Pérez-Belmonte LM, Carrasco-Sánchez FJ, Jansen-Chaparro S, De-Sousa-Baena M, Bueno-Fonseca J, et al. Cardiometabolic therapy and mortality in very old patients with diabetes hospitalized due to COVID-19. J Diabetes Res 2021;2021:7529013. https://doi.org/10.1155/2021/7529013.

[23] Scondotto S, et al. Are diabetes and its medications risk factors for the development of COVID-19? Data from a population-based study in Sicily. Nutr Metab Cardiovasc Dis 2021 Feb 8;31(2):396–8. https://doi.org/10.1016/j.numecd.2020.09.028.

[24] Sourj H, Aziz F, Bräuer A, Ciardi C, Clodi M, Fasching P, et al. COVID-19 fatality prediction in people with diabetes and prediabetes using a simple score upon hospital admission. Diabetes Obes Metab 2021 Feb;23(2):589–98. https://doi.org/10.1111/dom.14352.

[25] Warngny M, Potlier L, Gourdy P, Pichelin M, Amadou C, Benhamou PY, et al. Predictors of hospital discharge and mortality in patients with diabetes and COVID-19: updated results from the nationwide CORONADO study. Diabetologia 2021 Apr;64(4):778–94. https://doi.org/10.1007/s00125-020-05351-w.

[26] Lee YS, Jun HS. Anti-Inflammatory Effects of GLP-1-Based Therapies beyond Glucose Control. Mediators Inflamm 2016;2016:3094642. https://doi.org/10.1155/2016/3094642.

[27] Silverii GA, Monami M, Cernigliaro A, Vigneri E, Guarnotta V, Scandotto S, et al. Are diabetes and its medications risk factors for the development of COVID-19? Data from a population-based study in Sicily. Nutr Metab Cardiovasc Dis 2021 Feb 8;31(2):396–8. https://doi.org/10.1016/j.numecd.2020.09.028.

[28] Viby NE, Isidor MS, Buggeskov KB, Poulsen SS, Hansen JB, Søndergaard LM, et al. Glucagon-like peptide-1 receptor agonists in the era of COVID-19: Friend or foe? Diabetes Obes Metab 2021 Feb;23(2):589–98. https://doi.org/10.1111/dom.14352.

[29] Kendal EN, Isidor MS, Buggeskov KB, Poulsen SS, Hansen JB, Søndergaard LM, et al. GLP-1R agonists in COVID-19 treatment. Obes Med 2021 Sep 30. https://doi.org/10.1016/j.obesmed.2021.101074.

[30] Madan VM, Porcellati F, Strollo F, Gentile S. ACE2 and SARS-CoV-2 Infection and Monocyte Response through a HIF-1α Glycolysis-Dependent Axis. Cell Metab 2020 Sep 1;32(3):437–446.e5. https://doi.org/10.1016/j.cmet.2020.07.007.

[31] Lim S, Bae JH, Kwon HS, Nauck MA. COVID-19 and diabetes mellitus: from pathophysiology to clinical management. Nat Rev Endocrinol 2021 Jan;17(1):11–30. https://doi.org/10.1038/s41574-020-00435-4.

[32] Scondotto S, et al. Are diabetes and its medications risk factors for the development of COVID-19? Data from a population-based study in Sicily. Nutr Metab Cardiovasc Dis 2021 Feb 8;31(2):396–8. https://doi.org/10.1016/j.numecd.2020.09.028.

[33] Viby NE, Isidor MS, Buggeskov KB, Poulsen SS, Hansen JB, Søndergaard LM, et al. GLP-1R agonists in COVID-19 treatment. Obes Med 2021 Sep 30. https://doi.org/10.1016/j.obesmed.2021.101074.

[34] Lee YS, Jun HS. Anti-Inflammatory Effects of GLP-1-Based Therapies beyond Glucose Control. Mediators Inflamm 2016;2016:3094642. https://doi.org/10.1155/2016/3094642.

[35] Drucker DJ. Coronavirus Infections and Type 2 Diabetes-Mellitus: From Pathophysiology to Clinical Management. Endocr Rev. 2020 Sep;39. https://doi.org/10.1210/er.2020-00165.

[36] Monda VM, Porcellati F, Strollo F, Gentile S. ACE2 and SARS-CoV-2 Infection and Monocyte Response through a HIF-1α Glycolysis-Dependent Axis. Cell Metab 2020 Sep 1;32(3):437–446.e5. https://doi.org/10.1016/j.cmet.2020.07.007.

[37] Lim S, Bae JH, Kwon HS, Nauck MA. COVID-19 and diabetes mellitus: from pathophysiology to clinical management. Nat Rev Endocrinol 2021 Jan;17(1):11–30. https://doi.org/10.1038/s41574-020-00435-4.
Zhu T, Wu XL, Zhang W, Xiao M. Glucagon Like Peptide-1 (GLP-1) Modulates OVA-Induced Airway Inflammation and Mucus Secretion Involving a Protein Kinase A (PKA)-Dependent Nuclear Factor-κB (NF-κB) Signaling Pathway in Mice. Int J Mol Sci 2015 Aug 26;16(9):20195–211. https://doi.org/10.3390/ijms160920195.

Rogliani P, Matera MG, Calzetta L, Hanania NA, Page C, Rossi I, et al. Long-term observational study on the impact of GLP-1R agonists on lung function in diabetic patients. Respir Med 2019;154:86–92. https://doi.org/10.1016/j.rmed.2019.06.015.

Haffner SM. The metabolic syndrome: inflammation, diabetes mellitus, and cardiovascular disease. Am J Cardiol 2006 Jan 16;97(2A):3A–11A. https://doi.org/10.1016/j.ajcard.2005.11.010.

Ku HC, Chen WP, Su MJ. GLP-1 signaling preserves cardiac function in endotoxemic Fischer 344 and DPP4-deficient rats. Naunyn Schmiedebergs Arch Pharmacol 2010 Dec;382(5–6):463–74. https://doi.org/10.1007/s00210-010-0559-9.

Mirabelli M, Chiefari E, Fuccio L, Foti DP, Brunetti A. Potential Benefits and Harms of Novel Antidiabetic Drugs During COVID-19 Crisis. Int J Environ Res Public Health 2020 May 22;17(10):3664. https://doi.org/10.3390/ijerph17103664.

Gabery S, Salinas CG, Paulsen SJ, Ahnfelt-Ronne J, Alanentalo T, Baquero AF, et al. Semaglutide lowers body weight in rodents via distributed neural pathways. JCI Insight 2020 Mar 26;5(6). https://doi.org/10.1172/jci.insight.133429.e133429.

Davies MJ, Bergenstal R, Bode B, Kushner RF, Lewin A, Skjøth TV, et al. Efficacy of Liraglutide for Weight Loss Among Patients With Type 2 Diabetes: The SCALE Diabetes Randomized Clinical Trial. JAMA 2015 Aug 18;314(7):687–99. https://doi.org/10.1001/jama.2015.9676.

Blackman A, Foster GD, Zammit G, Rosenberg R, Aronne L, Wadden T, et al. Effect of liraglutide 3.0 mg in individuals with obesity and moderate or severe obstructive sleep apnea: the SCALE Sleep Apnea randomized clinical trial. Int J Obes (Lond) 2016 Aug;40(8):1310–9. https://doi.org/10.1038/ijo.2016.52.

Pi-Sunyer X, Astrup A, Fujioka K, Greenway F, Halpern A, Krempf M, et al. A Randomized, Controlled Trial of 3.0 mg of Liraglutide in Weight Management. N Engl J Med. 2015 Jul 2;373(1):11-22. https://doi.org/10.1056/NEJMoa1411892.

Belančić A. Gut microbiome dysbiosis and endotoxemia - Additional pathophysiological explanation for increased COVID-19 severity in obesity. Obes Med 2020 Dec;20. https://doi.org/10.1016/j.obmed.2020.100302.

Zhao L, Chen Y, Xia F, Abudukerimu B, Zhang W, Guo Y, et al. A Glucagon-Like Peptide-1 Receptor Agonist Lowers Weight by Modulating the Structure of Gut Microbiota. Front Endocrinol (Lausanne) 2018 May;17(9):233. https://doi.org/10.3389/fendo.2018.00233.